Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
A q-value threshold of 0.05 was used to identify all significant mixed effects associations16.Metabolites significantly increased with increased Procalcitonin over days 0 to 7.Metaboliteβ coefficient metabolitep-value− log10pq-valueSuper pathwaySub pathway3-Hydroxybutyrylcarnitine (C3-DC)4.171.19 E−043.926.78 E−04LipidShort-chain acylcarnitineSuccinylcarnitine (C4)4.227.58 E−043.123.17 E−03EnergyShort-chain acylcarnitineTiglyl carnitine (C5)4.429.86 E−054.015.89 E−04Amino acidShort-chain acylcarnitine2-Methylbutyroylcarnitine (C5)3.734.04 E−043.391.86 E−03Amino acidShort-chain acylcarnitineAdipoylcarnitine (C6-DC)4.421.50 E−054.821.20 E−04LipidShort-chain acylcarnitine3-Methyladipoylcarnitine (C7-DC)3.084.32 E−032.361.45 E−02LipidShort-chain acylcarnitineOctanoylcarnitine (C8)4.093.83 E−043.421.79 E−03LipidMedium-chain acylcarnitineSuberoylcarnitine (C8-DC)3.195.57 E: −043.252.45 E−03LipidMedium-chain acylcarnitinecis-4-Decenoylcarnitine (C10:1)4.127.12 E−043.152.99 E−03LipidMedium-chain acylcarnitineDecanoylcarnitine (C10)3.946.74 E−043.172.86 E−03LipidMedium-chain Acylcarnitine3-Methyladipate5.747.40 E−098.131.91 E−07LipidFatty acid, dicarboxylateAdipate3.004.31 E−032.371.45 E−02LipidFatty acid, dicarboxylate3-Hydroxyadipatea2.911.89 E−032.727.03 E−03LipidFatty acid, dicarboxylate2-Hydroxyadipate2.773.30 E−032.481.15 E−02LipidFatty acid, dicarboxylateheptenedioate (C7:1-DC)a3.081.83 E−032.746.83 E−03LipidFatty acid, dicarboxylateSuberate (C8-DC)4.269.47 E−054.025.80 E−04LipidFatty acid, dicarboxylateDodecanedioate (C12)3.413.01 E−043.521.46 E: 03LipidFatty acid, dicarboxylateDodecenedioate (C12:1-DC)a2.694.47 E−032.351.50 E−02LipidFatty acid, dicarboxylateHexadecanedioate (C16)3.432.75 E−043.561.35 E−03LipidFatty acid, dicarboxylateOctadecadienedioate (C18:2-DC)a3.812.86 E−043.541.40 E−03LipidFatty acid, dicarboxylateOctadecenedioate (C18:1-DC)a3.091.50 E−032.835.82 E−03LipidFatty acid, dicarboxylateOctadecanedioate (C18)2.517.54 E−032.122.32 E−02LipidFatty acid, dicarboxylateEicosanodioate (C20-DC)4.776.57 E−043.182.80 E−03LipidFatty acid, dicarboxylateMethylsuccinate7.441.87 E−109.738.31 E−09Amino acidBCAA metabolism3-Methylglutaconate6.467.79 E−098.111.96 E−07Amino acidBCAA metabolism2,3-Dihydroxy-2-methylbutyrate6.442.75 E−098.568.70 E−08Amino acidBCAA metabolism3-Hydroxy-2-ethylpropionate5.221.64 E−043.798.72 E−04Amino acidBCAA metabolismN-Acetylvaline5.196.79 E−043.172.87 E−03Amino acidBCAA metabolismbeta-Hydroxyisovalerate5.161.30 E−043.897.20 E−04Amino acidBCAA metabolismN-Acetylisoleucine4.252.35 E−032.638.50 E−03Amino acidBCAA metabolismEthylmalonate4.161.29 E−032.895.21 E−03Amino acidBCAA metabolismIsovalerylglycine2.291.52 E−021.824.08 E−02Amino acidBCAA metabolismSedoheptulose4.782.40 E−054.621.83 E−04CarbohydratePentose metabolismArabonate/xylonate4.375.22 E−043.282.35 E−03CarbohydratePentose metabolismRibonate3.983.03 E−032.521.07 E−02CarbohydratePentose metabolismArabinose3.601.31 E−032.885.26 E−03CarbohydratePentose metabolismRibitol3.261.30 E−021.893.61 E−02CarbohydratePentose metabolismUsing repeated measures data (day 0, 3 and 7), the association between relative quantitation of each individual metabolite noted above and Procalcitonin levels over time were determined utilizing linear mixed-effects models correcting for age, sex, baseline 25(OH)D, absolute increase in 25(OH)D, SAPS II, admission diagnosis, plasma day and an individual subject-specific random-intercept.
Source: Multiple time point data. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Procalcitonin metabolomics in the critically ill reveal relationships between inflammation intensity and energy utilization pathways
Study design awaiting verification · Scientific Reports · 2021
Original publication title
Procalcitonin metabolomics in the critically ill reveal relationships between inflammation intensity and energy utilization pathways
© The Author(s) 2021
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Procalcitonin is a biomarker of systemic inflammation and may have importance in the immune response. The metabolic response to elevated procalcitonin in critical illness is not known. The response to inflammation is vitally important to understanding metabolism alterations during extreme stress. Our aim was to determine if patients with elevated procalcitonin have differences in the metabolomic response to early critical illness. We performed a metabolomics study of the VITdAL-ICU trial where subjects received high dose vitamin D3 or placebo.
Mixed-effects modeling was used to study changes in metabolites over time relative to procalcitonin levels adjusted for age, Simplified Acute Physiology Score II, admission diagnosis, day 0 25-hydroxyvitamin D level, and the 25-hydroxyvitamin D response to intervention. With elevated procalcitonin, multiple members of the short and medium chain acylcarnitine, dicarboxylate fatty acid, branched-chain amino acid, and pentose phosphate pathway metabolite classes had significantly positive false discovery rate corrected associations. Further, multiple long chain acylcarnitines and lysophosphatidylcholines had significantly negative false discovery rate corrected associations with elevated procalcitonin.
Gaussian graphical model analysis revealed functional modules specific to elevated procalcitonin. Our findings show that metabolite differences exist with increased procalcitonin indicating activation of branched chain amino acid dehydrogenase and a metabolic shift.
Authors’ abstract
Procalcitonin is a biomarker of systemic inflammation and may have importance in the immune response. The metabolic response to elevated procalcitonin in critical illness is not known. The response to inflammation is vitally important to understanding metabolism alterations during extreme stress. Our aim was to determine if patients with elevated procalcitonin have differences in the metabolomic response to early critical illness. We performed a metabolomics study of the VITdAL-ICU trial where subjects received high dose vitamin D3 or placebo.
Mixed-effects modeling was used to study changes in metabolites over time relative to procalcitonin levels adjusted for age, Simplified Acute Physiology Score II, admission diagnosis, day 0 25-hydroxyvitamin D level, and the 25-hydroxyvitamin D response to intervention. With elevated procalcitonin, multiple members of the short and medium chain acylcarnitine, dicarboxylate fatty acid, branched-chain amino acid, and pentose phosphate pathway metabolite classes had significantly positive false discovery rate corrected associations. Further, multiple long chain acylcarnitines and lysophosphatidylcholines had significantly negative false discovery rate corrected associations with elevated procalcitonin.
Gaussian graphical model analysis revealed functional modules specific to elevated procalcitonin. Our findings show that metabolite differences exist with increased procalcitonin indicating activation of branched chain amino acid dehydrogenase and a metabolic shift.
Publication and source details
Original title: Procalcitonin metabolomics in the critically ill reveal relationships between inflammation intensity and energy utilization pathways
Hirotada Kobayashi; Karin Amrein; Jessica A. Lasky-Su; Kenneth B. Christopher
Scientific Reports · 2021
© The Author(s) 2021https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.National Institute of HealthR01 GM115774Christopher Kenneth B.Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T11:31:24.053764+00:00
DOI: 10.1038/s41598-021-02679-0 · PMC8636627